Scarica l'app Stockscreener
12.87
5.49%
0.67
Dopo l'orario di chiusura:
12.87
Precedente Chiudi:
$12.20
Aprire:
$12.3
Volume 24 ore:
787.56K
Relative Volume:
0.79
Capitalizzazione di mercato:
$710.99M
Reddito:
$88.24M
Utile/perdita netta:
$-160.90M
Rapporto P/E:
-4.8307
EPS:
-2.6642
Flusso di cassa netto:
$-129.35M
1 W Prestazione:
+1.34%
1M Prestazione:
-5.58%
6M Prestazione:
+31.73%
1 anno Prestazione:
+29.22%
Intervallo 1D:
$12.04
$13.01
Intervallo di 1 settimana:
$11.99
$13.47
Portata 52W:
$6.96
$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
12.87 | 710.99M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2026-07-31 | Iniziato | B. Riley Securities | Buy |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-11-07 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com Nigeria
4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com India
CEO David Kirn sells 58,061 and 272 shares of 4D Molecular Therapeutics (FDMT) under a trading plan. - Stock Titan
4D Molecular Therapeutics Officer David Kirn Files Form 144 for Sale of 58,333 Shares - Kalkine Media
Officer David Kirn plans to sell 58,333 shares of 4D Molecular Therapeutics (FDMT). - Stock Titan
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com UK
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan
4D Molecular Therapeutics (Nasdaq:FDMT)Stock Analysis - Simply Wall Street
4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - Yahoo Finance
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK
Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - quiverquant.com
Seven new employees get 96,000 stock units from 4DMT - stocktitan.net
4DMT Announces New Employment Inducement Grants - GlobeNewswire
FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView
FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com India
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - Investing.com
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 584 common shares for $8,176 - Bitget
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com India
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4 D Molecular Therapeutics Inc Azioni (FDMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| David Kirn | Officer |
Oct 05 '26 |
Proposed Sale |
12.92 |
58,333 |
753,662 |
0 |
| Bizily Scott | Chief Legal Officer |
Sep 16 '26 |
Sale |
13.65 |
1,635 |
22,318 |
8,617 |
| Bizily Scott | Chief Legal Officer |
Sep 16 '26 |
Option Exercise |
4.14 |
1,635 |
6,769 |
10,252 |
| Kirn David | See Remarks |
Sep 14 '26 |
Sale |
13.90 |
58,333 |
811,004 |
767,486 |
| David Kirn | Officer |
Sep 14 '26 |
Proposed Sale |
13.76 |
58,333 |
802,662 |
0 |
| Bizily Scott | Chief Legal Officer |
Sep 01 '26 |
Option Exercise |
6.49 |
584 |
3,790 |
9,201 |
| Bizily Scott | Chief Legal Officer |
Sep 01 '26 |
Sale |
14.00 |
584 |
8,176 |
8,617 |
| Kirn David | See Remarks |
Aug 19 '26 |
Sale |
15.75 |
69,076 |
1,088,273 |
825,819 |
| David Kirn | Officer |
Aug 19 '26 |
Proposed Sale |
16.76 |
69,076 |
1,157,714 |
0 |
| Kirn David | See Remarks |
Aug 19 '26 |
Option Exercise |
4.14 |
50,000 |
207,000 |
894,895 |
0.43%
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):